UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

13-5315170

(State of Incorporation)

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.05 par value

PFE

New York Stock Exchange

0.000% Notes due 2020

PFE20A

New York Stock Exchange

0.250% Notes due 2022

PFE22

New York Stock Exchange

1.000% Notes due 2027

PFE27

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

At November 4, 2019, 5,534,122,364 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended September 29, 2019 and

September 30, 2018

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 29, 2019

and September 30, 2018

Condensed Consolidated Balance Sheets as of September 29, 2019 and December 31, 2018

Condensed Consolidated Statements of Equity for the three and nine months ended September 29, 2019 and

September 30, 2018

Condensed Consolidated Statements of Cash Flows for the nine months ended September 29, 2019 and

September 30, 2018

10

Notes to Condensed Consolidated Financial Statements

12

Review Report of Independent Registered Public Accounting Firm

52

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

53

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

114

Item 4.

Controls and Procedures

114

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

115

Item 1A.

Risk Factors

115

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

116

Item 3.

Defaults Upon Senior Securities

116

Item 4.

Mine Safety Disclosures

116

Item 5.

Other Information

116

Item 6.

Exhibits

117

Signature

118

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2018 Financial Report

Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018

2018 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2018

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

Akcea

Akcea Therapeutics, Inc.

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

Anacor

Anacor Pharmaceuticals, Inc.

AOCI

Accumulated Other Comprehensive Income

Array

Array BioPharma Inc.

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Bain Capital

Bain Capital Private Equity and Bain Capital Life Sciences

Bamboo

Bamboo Therapeutics, Inc.

Biopharma

Pfizer Biopharmaceuticals Group

BMS

Bristol-Myers Squibb Company

CAR T

chimeric antigen receptor T cell

CDC

U.S. Centers for Disease Control and Prevention

Cerevel

Cerevel Therapeutics, LLC

cGMP

current Good Manufacturing Practices

Citibank

Citibank, N.A.

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and

New Zealand

EGFR

epidermal growth factor receptor

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),

Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development organization

GSK

GlaxoSmithKline plc

GS&Co.

Goldman, Sachs & Co. LLC

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

Ionis

Ionis Pharmaceuticals, Inc.

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson

JV

Joint Venture

King

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCC

Merkel cell carcinoma

MCO

managed care organization

mCRC

metastatic colorectal cancer

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation LLC (formerly Medivation, Inc.)

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

Mylan

Mylan N.V.

NDA

new drug application

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

pharmacy benefit manager

Pharmacia

Pharmacia Corporation

PP&E

property, plant & equipment

PsA

psoriatic arthritis

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2019

RA

rheumatoid arthritis

RCC

renal cell carcinoma

R&D

research and development

ROU

right of use

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

Shire

Shire International GmbH

SI&A

selling, informational and administrative

S&P

Standard and Poor s

TCJA

legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Therachon

Therachon Holding AG

UC

ulcerative colitis

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

VBP

Volume-based procurement program

WRDM

Worldwide Research, Development and Medical

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

September 29,

2019

September 30,

2018

September 29,

2019

September 30,

2018

Revenues

12,680

13,298

39,062

39,670

Costs and expenses:

Cost of sales(a)

2,602

2,694

7,611

8,173

Selling, informational and administrative expenses(a)

3,260

3,494

10,110

10,448

Research and development expenses(a)

2,283

2,008

5,827

5,549

Amortization of intangible assets

1,212

1,253

3,578

3,640

Restructuring charges and certain acquisition-related costs

365

85

295

172

(Gain) on completion of Consumer Healthcare JV transaction

(8,087

(8,087

Other (income)/deductions net

319

(414

537

(1,143

Income from continuing operations before provision for taxes on income

10,727

4,177

19,190

12,831

Provision for taxes on income

3,047

66

2,566

1,270

Income from continuing operations

7,680

4,111

16,625

11,562

Discontinued operations net of tax

11

10

Net income before allocation to noncontrolling interests

7,684

4,122

16,628

11,571

Less: Net income attributable to noncontrolling interests

19

25

Net income attributable to Pfizer Inc.

7,680

4,114

16,609

11,546

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

1.38

0.70

2.98

1.96

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

1.38

0.70

2.98

1.96

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

1.36

0.69

2.92

1.92

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

1.36

0.69

2.92

1.92

Weighted-average shares basic

5,545

5,875

5,581

5,899

Weighted-average shares diluted

5,649

5,986

5,690

5,998

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 29,

2019

September 30,

2018

September 29,

2019

September 30,

2018

Net income before allocation to noncontrolling interests

7,684

4,122

16,628

11,571

Foreign currency translation adjustments, net

(468

(567

(628

(507

Reclassification adjustments(a)

268

(2

270

(22

(200

(569

(358

(530

Unrealized holding gains on derivative financial instruments, net

150

222

241

236

Reclassification adjustments for (gains)/losses included in net income(b)

(29

(235

(372

119

122

(13

(131

355

Unrealized holding gains/(losses) on available-for-sale securities, net

15

149

48

(65

Reclassification adjustments for (gains)/losses included in net income(b)

(7

(36

30

(67

Reclassification adjustments for unrealized gains included in Retained earnings(c)

(462

112

77

(595

Benefit plans: actuarial gains/(losses), net

(171

(175

114

Reclassification adjustments related to amortization

60

60

180

183

Reclassification adjustments related to settlements, net

38

42

40

108

Other

42

49

60

69

(31

158

105

474

Benefit plans: prior service costs and other, net

(1

Reclassification adjustments related to amortization of prior service costs and other, net

(44

(46

(137

(137

Reclassification adjustments related to curtailments of prior service costs and other, net

(46

(4

(46

(18

Other

(88

(50

(180

(154

Other comprehensive loss, before tax

(190

(361

(486

(449

Tax provision on other comprehensive loss

84

62

50

667

Other comprehensive loss before allocation to noncontrolling interests

(275

(422

(536

(1,116

Comprehensive income before allocation to noncontrolling interests

7,409

3,700

16,092

10,455

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(6

Comprehensive income attributable to Pfizer Inc.

7,415

3,700

16,084

10,450

(a)

For the third quarter and first nine months of 2019, the foreign currency translation adjustments are primarily reclassified into (Gain) on completion of Consumer Healthcare JV transaction in the condensed consolidated statements of income as a result of the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK. See Note 2B. The remaining foreign currency translation adjustments are reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(b)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(c)

For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

September 29,

2019

December 31,

2018

(Unaudited)

Assets

Cash and cash equivalents

2,785

1,139

Short-term investments

6,302

17,694

Trade accounts receivable, less allowance for doubtful accounts: 2019 $541; 2018 $541

9,439

8,025

Inventories

8,222

7,508

Current tax assets

3,730

3,374

Other current assets

2,954

2,461

Assets held for sale

29

9,725

Total current assets

33,459

49,926

Equity-method investments

15,999

181

Long-term investments

2,723

2,586

Property, plant and equipment, less accumulated depreciation: 2019 $16,728; 2018 $16,591

13,701

13,385

Identifiable intangible assets, less accumulated amortization

38,995

35,211

Goodwill

58,665

53,411

Noncurrent deferred tax assets and other noncurrent tax assets

1,984

1,924

Other noncurrent assets

4,920

2,799

Total assets

170,446

159,422

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2019 $2,431; 2018 $4,776

16,617

8,831

Trade accounts payable

3,942

4,674

Dividends payable

1,992

2,047

Income taxes payable

1,892

1,265

Accrued compensation and related items

2,369

2,397

Other current liabilities

10,160

10,753

Liabilities held for sale

1,890

Total current liabilities

36,974

31,858

Long-term debt

36,044

32,909

Pension benefit obligations, net

5,103

5,272

Postretirement benefit obligations, net

1,321

1,338

Noncurrent deferred tax liabilities

6,724

3,700

Other taxes payable

12,504

14,737

Other noncurrent liabilities

6,381

5,850

Total liabilities

105,051

95,664

Commitments and Contingencies

Preferred stock

18

19

Common stock

468

467

Additional paid-in capital

87,099

86,253

Treasury stock

(110,795

(101,610

Retained earnings

100,113

89,554

Accumulated other comprehensive loss

(11,801

(11,275

Total Pfizer Inc. shareholders equity

65,103

63,407

Equity attributable to noncontrolling interests

293

351

Total equity

65,396

63,758

Total liabilities and equity

170,446

159,422

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, June 30, 2019

458

18

9,363

468

86,963

(3,801

(110,786

94,440

(11,535

59,568

357

59,924

Net income

7,680

7,680

7,684

Other comprehensive income/(loss), net of tax

(265

(265

(9

(275

Cash dividends declared:

Common stock

(2,006

(2,006

(2,006

Preferred stock

Noncontrolling interests

Share-based payment transactions

136

(8

128

128

Purchases of common stock

(34

Preferred stock conversions and redemptions

(8

(1

(1

Other(a)

(61

(61

Balance, September 29, 2019

449

18

9,366

468

87,099

(3,835

(110,795

100,113

(11,801

65,103

293

65,396

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance July 1, 2018

502

20

9,303

465

84,898

(3,438

(95,463

89,860

(10,003